Dorsomorphin (Compound C): Precision AMPK and BMP Inhibition in Autophagy and Muscle Metabolism Research

Introduction

Dorsomorphin, also known as Compound C, has emerged as a cornerstone research tool for dissecting cellular energy regulation and differentiation pathways. As a selective, cell-permeable, and reversible ATP-competitive AMPK inhibitor, Dorsomorphin enables researchers to interrogate the AMP-activated protein kinase (AMPK) signaling pathway and the bone morphogenetic protein (BMP)/Smad axis with exceptional specificity. The dual-targeting properties of Dorsomorphin (Compound C) have uniquely positioned it in studies ranging from autophagy regulation and skeletal muscle metabolism to neural stem cell differentiation and iron homeostasis.

While prior articles have expertly outlined Dorsomorphin’s mechanistic versatility (see this dual-pathway analysis), this article advances the discussion by deeply integrating how Dorsomorphin enables the controlled disruption of autophagic and metabolic pathways in complex disease models—particularly, its ability to elucidate the AMPK/PINK1/Parkin-mediated mitophagy pathway in sarcopenic obesity and beyond.

Mechanism of Action of Dorsomorphin (Compound C)

AMPK Inhibition: Specificity and Downstream Effects

At the molecular level, Dorsomorphin exhibits a high affinity (Ki = 109 nM) for AMPK, functioning as an ATP-competitive inhibitor. This selectivity is demonstrated by its limited off-target activity against related kinases such as protein kinase A, protein kinase C, and Janus kinase 3. Inhibition of AMPK by Dorsomorphin blocks downstream phosphorylation events, notably suppressing acetyl-CoA carboxylase (ACC) phosphorylation by up to 80%. This disrupts lipid metabolism and curtails autophagic proteolysis—a central process in cellular energy homeostasis and quality control. Critically, these effects can be leveraged for the inhibition of AMPK activity in hepatocytes and other metabolically active cell types.

BMP/Smad Pathway Modulation

Dorsomorphin also inhibits BMP signaling by preventing the phosphorylation of Smad 1/5/8 proteins, which mediate transcriptional responses to BMP ligands. This BMP4-induced SMAD phosphorylation inhibition not only impacts developmental pathways but also reduces heterotopic ossification and hepatic hepcidin gene transcription, thereby modulating iron metabolism. The ability to simultaneously inhibit both AMPK and BMP/Smad pathways distinguishes Dorsomorphin from conventional single-pathway inhibitors and broadens its application in disease modeling and cell fate specification studies.

Integrating Reference-Driven Insights: AMPK/PINK1/Parkin-Mediated Mitophagy

Autophagy Regulation and Skeletal Muscle Metabolism

Recent research has highlighted the pivotal role of AMPK in regulating mitophagy, particularly in the context of skeletal muscle atrophy induced by metabolic dysfunction. In a seminal study (Ren et al., 2025), the therapeutic potential of Lycium barbarum polysaccharide (LBP) was shown to depend on activation of the AMPK/PINK1/Parkin pathway to promote mitophagy, restore mitochondrial function, and mitigate muscle atrophy in high-fat diet models. Notably, the beneficial effects of LBP were abrogated upon administration of an AMPK inhibitor—specifically, Dorsomorphin. This finding firmly establishes Dorsomorphin as a key experimental tool for dissecting the mechanistic underpinnings of autophagy regulation and mitochondrial quality control in muscle and metabolic disease models.

Through the targeted inhibition of AMPK, Dorsomorphin enables researchers to:

• Elucidate the dependency of mitophagic flux on AMPK activity
• Probe the crosstalk between energy sensing, mitochondrial turnover, and muscle mass regulation
• Dissect the impact of metabolic interventions on autophagy and cellular homeostasis

This approach provides a powerful contrast to previous content—which has focused on dual-pathway insights—by emphasizing Dorsomorphin’s utility in mechanistic, pathway-focused interrogations of autophagy and metabolism (see this article’s emphasis on mitochondrial quality control).

Iron Metabolism Modulation and Hepcidin Regulation

Dorsomorphin’s inhibition of BMP signaling and subsequent suppression of hepcidin transcription in the liver results in increased serum iron levels. This property is particularly relevant for studies exploring the intersection of iron metabolism, erythropoiesis, and systemic metabolic regulation. By modulating BMP/Smad signaling with Dorsomorphin, researchers can experimentally alter iron homeostasis and probe the pathophysiology of disorders such as anemia of inflammation or hemochromatosis—an application avenue that extends beyond the core focus of previous Dorsomorphin reviews.

Advanced Applications in Cancer, Stem Cell, and Disease Model Research

Cancer Research: Dissecting Metabolic Vulnerabilities

The AMPK signaling pathway is a central regulator of cellular energy status and a key modulator of cancer cell survival under metabolic stress. Dorsomorphin (Compound C) has been instrumental in identifying AMPK-dependent metabolic adaptations in cancer models. By selectively inhibiting AMPK, researchers can reveal vulnerabilities in tumor cell metabolism, uncovering potential therapeutic targets for metabolic intervention. This ATP-competitive AMPK inhibitor thereby complements genetic knockdown approaches, allowing for rapid, reversible modulation of pathway activity in preclinical studies.

Neural Stem Cell Differentiation and BMP Signaling

In addition to metabolic applications, Dorsomorphin’s inhibition of BMP/Smad signaling has proven pivotal in neural induction and self-renewal of human embryonic stem cells. By blocking BMP activity, Dorsomorphin promotes neural lineage specification, offering a powerful approach for generating neural progenitors and modeling neurodevelopmental processes in vitro. This strategy enables researchers to finely discriminate between BMP-dependent and -independent differentiation cues, enhancing experimental resolution in stem cell biology.

Autophagy Regulation in Disease Models

Building on the findings of Ren et al. (2025), Dorsomorphin enables the experimental dissection of mitophagy and autophagy pathways in models of sarcopenic obesity, metabolic syndrome, and muscle atrophy. By precisely inhibiting AMPK, Dorsomorphin allows for the validation of autophagy-dependent therapeutic effects and provides a rigorous control for pathway-specific interventions.

Comparative Analysis with Alternative Approaches

Chemical Inhibitors Versus Genetic Manipulation

While genetic knockdown or knockout of AMPK or BMP pathway components offers permanent pathway disruption, chemical inhibition with Dorsomorphin provides temporal control and reversibility—crucial for time-course studies and acute pathway modulation. Furthermore, Dorsomorphin’s dual inhibition profile allows for the simultaneous interrogation of metabolic and differentiation pathways, a feature not readily achievable with single-target genetic approaches.

Advantages Over Other Inhibitors

Alternative AMPK inhibitors such as SBI-0206965 or dorsomorphin analogs may vary in selectivity and potency. Dorsomorphin’s established selectivity profile and solubility characteristics (insoluble in water/ethanol, soluble in DMSO ≥8.49 mg/mL with warming and ultrasonic treatment) make it a reliable choice for diverse cell types and animal models. Its recommended concentrations (4–40 μM in cell culture, 10 mg/kg i.p. in animal models) facilitate straightforward experimental design and reproducibility.

This article distinguishes itself from protocol- and troubleshooting-focused reviews (such as this guide) by offering a mechanistic, application-driven analysis that bridges cellular, molecular, and translational research domains.

Technical Handling and Best Practices

Dorsomorphin (Compound C) is supplied as a solid by APExBIO and should be stored at -20°C. For optimal results, solutions should be freshly prepared in DMSO and used promptly, as long-term storage of solutions is not recommended. When working with cell culture or animal models, always adhere to recommended concentration ranges and validate inhibition specificity in the chosen system. For a complete technical specification and ordering information, refer to the Dorsomorphin (Compound C) product page (SKU: B3252).

Conclusion and Future Outlook

Dorsomorphin (Compound C) stands as a benchmark dual-pathway inhibitor, offering unparalleled control over the AMPK signaling pathway and BMP/Smad axis. Its utility extends from fundamental analyses of autophagy regulation—where it has been pivotal in clarifying the AMPK/PINK1/Parkin-mediated mitophagy mechanism (see Ren et al., 2025)—to advanced disease modeling in cancer, metabolism, and stem cell biology. Looking ahead, the precision and versatility of Dorsomorphin, especially when sourced from trusted suppliers like APExBIO, will continue to empower researchers to unravel complex biological networks and identify actionable targets for therapeutic development.

For researchers seeking deeper experimental or protocol guidance, we recommend supplementing this mechanistic overview with workflow- and troubleshooting-focused resources such as this practical guide. Meanwhile, this article provides a unique, integrative perspective on Dorsomorphin’s transformative role in modern biomedical research, bridging the gap between pathway dissection and translational innovation.